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https://doi.org/10.1186/s12931-020-01388-yRESEARCH Open AccessBenefits of glycopyrrolate/formoterol
fumarate metered dose inhaler (GFF MDI)
in improving lung function and reducing
exacerbations in patients with moderate-to-
very severe COPD: a pooled analysis of the
PINNACLE studies
Fernando J. Martinez1*, Brian J. Lipworth2, Klaus F. Rabe3, David J. Collier4, Gary T. Ferguson5, Sanjay Sethi6,
Gregory J. Feldman7, Gerald O’Brien8, Martin Jenkins9 and Colin Reisner10Abstract
Background: The Phase III PINNACLE studies assessed the efficacy and safety of glycopyrrolate/formoterol fumarate
metered dose inhaler (GFF MDI), a dual long-acting bronchodilator for chronic obstructive pulmonary disease
(COPD). Here we present a pre-specified pooled analysis of PINNACLE-1, PINNACLE-2, and PINNACLE-4.
Methods: PINNACLE-1, -2, and -4 were multicenter, double-blind, randomized controlled trials that enrolled patients
with moderate-to-very severe COPD, with no requirement for exacerbation history or a high symptom burden.
Patients received GFF MDI 18/9.6 μg, glycopyrrolate (GP) MDI 18 μg, formoterol fumarate (FF) MDI 9.6 μg, or placebo
MDI, twice-daily for 24 weeks. The primary endpoint of the pooled analysis was the change from baseline in
morning pre-dose trough forced expiratory volume in 1 s (FEV1) at week 24. Secondary endpoints included COPD
exacerbations and clinically important deterioration (CID). Adverse events were also assessed.
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Results: The pooled intent-to-treat population included 4983 patients; of these, 61.9% had a COPD assessment test
(CAT) score ≥15, and 25.0% had experienced ≥1 moderate/severe exacerbation in the past year. At week 24, GFF MDI
improved morning pre-dose trough FEV1 versus GP MDI (least squares mean [LSM] difference [95% confidence interval
(CI)]: 59mL [43, 75]), FF MDI (65 mL [48, 81]), and placebo MDI (146mL [125, 166]); all p < 0.0001. GFF MDI reduced the
risk of a moderate/severe exacerbation by 18% (p = 0.0168), 15% (p = 0.0628), and 28% (p = 0.0012) compared
with GP MDI, FF MDI, and placebo MDI, respectively. In general, exacerbation risk reduction with GFF MDI
versus comparators was greater in subgroups of symptomatic patients (CAT ≥15) and those who had an
exacerbation history, than in the pooled intent-to-treat population. The risk of CID was also lower with GFF MDI versus
GP MDI (23% decrease), FF MDI (17%), and placebo MDI (49%); all p < 0.0001. All treatments were well tolerated, with
no unexpected safety signals.
Conclusions: This pooled analysis of the PINNACLE studies demonstrated that GFF MDI improved lung function and
reduced the risk of exacerbations compared with monocomponents and placebo in patients with COPD. Exacerbation
reductions with GFF MDI versus comparators were generally greater in patients with higher symptom burden and
those with exacerbation history.
Trial registration: ClinicalTrials.gov NCT01854645, NCT01854658, and NCT02343458. Registered 13 May 2013 (NCT01
854645, NCT01854658) and 6 January 2015 (NCT02343458).
Keywords: Chronic obstructive pulmonary disease, Clinically important deterioration, Exacerbations, Fixed-dose
combination, Formoterol fumarate dihydrate, GFF MDI, Glycopyrronium, LAMA/LABA, Metered dose inhaler, SymptomaticIntroduction
Reducing the future risk of chronic obstructive pulmon-
ary disease (COPD) exacerbations is one of the main
goals for the treatment of the disease [1]. Exacerbations
cause a substantial impact on patients’ lives; they are as-
sociated with a greater rate of lung function decline [2]
and worse quality of life [3] compared with patients who
do not experience exacerbations. The Global Initiative
for Chronic Obstructive Lung Disease (GOLD) 2020 re-
port recommends long-acting muscarinic antagonist
(LAMA)/long-acting β2-agonist (LABA) combinations
for prevention of exacerbations in some patients, prior
to escalation to triple therapy [1]. However, there are
limited data regarding the benefit of LAMA/LABA
fixed-dose combinations (FDCs) versus the correspond-
ing monocomponents in reducing exacerbations in
patients with COPD [4–6].
Glycopyrrolate/formoterol fumarate metered dose in-
haler 18/9.6 μg (GFF MDI; Bevespi Aerosphere®), an
FDC of the LAMA glycopyrrolate and the LABA formo-
terol fumarate, delivered using innovative co-suspension
delivery technology, is approved as a maintenance treat-
ment for COPD. The efficacy and safety of GFF MDI
compared with its respective monocomponents have
been demonstrated in patients with moderate-to-very
severe COPD in the pivotal Phase III studies
PINNACLE-1, PINNACLE-2, and PINNACLE-4
(NCT01854645, NCT01854658, and NCT02343458; all
24 weeks), and PINNACLE-3 (NCT01970878; 28-week
safety extension study of PINNACLE-1 and -2), in
patients from the USA, Asia, Europe, Australia, and New
Zealand [7–9]. However, the individual pivotal studies,which were not enriched for patients with a high risk of
exacerbations, were not sufficiently powered to interro-
gate the impact of GFF MDI on exacerbations. Yet, a
pooled analysis of these studies provides a reasonably
large body of evidence in which to assess the exacerba-
tion benefits of GFF MDI.
The objective of this pre-specified, integrated analysis
of individual patient data from the three 24-week stud-
ies, PINNACLE-1, -2, and -4, was to further evaluate the
efficacy of GFF MDI, by using the combined data set to
provide a more precise estimation of the treatment
effects on lung function, COPD exacerbations, and clin-
ically important deterioration (CID) endpoints in the
pooled population, and to evaluate safety in a large
patient population.
Methods
Study design, patients, and treatments
Study designs, eligibility criteria, treatments, and statistical
methods for the studies included in this analysis have been
reported previously [7, 9]. In brief, PINNACLE-1, -2, and
-4 were three Phase III multicenter, randomized, double-
blind, parallel-group, placebo-controlled trials (Fig. 1).
PINNACLE-1 was conducted across sites in the USA,
Australia, and New Zealand; PINNACLE-2 encompassed
sites in the USA; and PINNACLE-4 included sites across
Asia, Europe, and the USA. Each study enrolled patients
who were 40–80 years of age and current or ex-smokers
(history of ≥10 pack-years), with moderate-to-very severe
COPD, defined by a post-bronchodilator forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) ratio
< 0.7, and a post-bronchodilator FEV1 < 80% predicted
Fig. 1 PINNACLE-1, -2, and -4 study design. PINNACLE-1 also included an open-label tiotropium arm (not shown). FF, formoterol fumarate;
GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; MDI, metered dose inhaler
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predicted normal (i.e. very severe airflow limitation) were
required to have a post-bronchodilator FEV1 ≥ 750mL.
There was no exacerbation history requirement or mini-
mum symptom score for study entry, in contrast to several
randomized controlled trials of other LAMA/LABA com-
binations that enrolled entirely symptomatic populations,
e.g. patients with a modified Medical Research Council
dyspnea scale (mMRC) score ≥2 [10], or those meeting a
symptom diary score threshold [11].
Exclusion criteria included a current diagnosis of
asthma, concomitant respiratory disorders including, but
not limited to, lung cancer and alpha-1 antitrypsin defi-
ciency, or any underlying renal, liver, endocrine, cardiac,
or other medical condition that, in the opinion of the in-
vestigator, may have influenced the study results or the
patient’s ability to participate. Patients were randomized
to 24 weeks’ treatment with GFF MDI 18/9.6 μg (also
known as, and equivalent to, glycopyrronium/formoterol
fumarate dihydrate 14.4/10.0 μg), glycopyrrolate (GP)
MDI 18 μg, formoterol fumarate (FF) MDI 9.6 μg, or
matched placebo MDI (all administered as two actua-
tions twice daily). Also, the PINNACLE-1 study included
an open-label tiotropium arm (one capsule inhaled once
daily) as an active control group, but this was not in-
cluded in the pooled analyses as it was only assessed in
one of the three studies.
Patients using an inhaled corticosteroid (ICS) as part
of their maintenance therapy at baseline were permitted
to continue with the ICS component, providing they had
been on a stable dose for ≥4 weeks prior to screening.
Sponsor-provided albuterol sulfate (Ventolin HFA) was
permitted as rescue medication throughout the studies.
The PINNACLE studies were conducted in accordance
with Good Clinical Practice, including the InternationalConference on Harmonisation guidelines and the Dec-
laration of Helsinki. All patients provided written
informed consent prior to screening.
Outcomes included in the pooled analysis
The change from baseline in morning pre-dose trough
FEV1 at week 24 (for the US statistical analysis ap-
proach) or over 24 weeks (EU approach) was the primary
or co-primary endpoint of each study and also the pri-
mary endpoint of the pooled analysis. Secondary end-
points of the pooled analysis included peak change from
baseline in FEV1 within 2 h post-dose, rate of moderate
or severe COPD exacerbations, time to the first moder-
ate or severe COPD exacerbation, time to treatment fail-
ure, and time to first CID. A moderate exacerbation was
defined as an exacerbation that required treatment with
systemic corticosteroids and/or antibiotics, and a severe
exacerbation was defined as one that resulted in
hospitalization or death. Treatment failure was defined
as a moderate or severe COPD exacerbation or discon-
tinuation from study for any reason. A CID was defined
as a ≥100 mL reduction in morning pre-dose trough
FEV1 and/or a worsening (increase) of ≥4 units in St
George’s Respiratory Questionnaire (SGRQ) at any post-
baseline study visit, and/or the occurrence of a
treatment-emergent moderate or severe COPD exacer-
bation. While we report both the rate and the time to
the first moderate or severe COPD exacerbation here,
the time to first exacerbation may provide a better esti-
mation of the treatment benefits compared with the rate
of moderate or severe exacerbations, as patients with a
severe COPD exacerbation or >2 moderate COPD exac-
erbations were discontinued from the PINNACLE stud-
ies. Pooled safety analyses included adverse events and
serious adverse events.
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The statistical analysis plan for the pooled analyses of
PINNACLE-1, -2, and -4 was developed prior to the
unblinding of PINNACLE-4 and was based upon an up-
date to a pre-specified analysis plan written prior to the
unblinding of PINNACLE-1 and -2. Pooled analyses of
spirometry, exacerbations, and treatment failure were in-
cluded in the original analysis plan, with the COPD as-
sessment test (CAT) ≥15 subgroup and CID analyses
defined in the pooled analysis plan prior to the unblind-
ing of PINNACLE-4. The pooled intent-to-treat (ITT)
and safety populations included patients who were ran-
domized to treatment and received any study treatment
in PINNACLE-1, -2, or -4. Patients who received open-
label tiotropium in PINNACLE-1 were excluded from
both the ITT and safety populations as there was no tio-
tropium arm in the other PINNACLE studies. There was
no control for multiplicity for the pooled data as this
had been performed in the individual studies.
Twenty-two patients participated at multiple sites
within a study, or in more than one of the PINNACLE
studies. These patients were excluded from both the
pooled ITT and safety populations if they had overlap-
ping treatment exposure. If exposure did not overlap,
data from their first exposure were included in both
populations, while subsequent exposure data were in-
cluded only in the safety population.
In addition to the pooled ITT population, we report
results for exacerbation, treatment failure, and CID end-
points from subgroups of patients who were symptom-
atic (defined as a CAT score ≥15 at baseline) or with a
history of exacerbations (defined as ≥1 moderate or se-
vere exacerbations in the year prior to the baseline visit).
The CAT ≥15 subgroup was pre-defined as the symp-
tomatic population in the pooled analysis plan based on
findings from PINNACLE-1 and -2 [6], while the ana-
lyses in the exacerbation history subgroup were pro-
duced post-hoc, to understand the consistency of the
findings.
The change from baseline in morning pre-dose trough
FEV1 and peak change from baseline in FEV1 within 2 h
post-dose were analyzed using a linear repeated mea-
sures model, with baseline FEV1, percent reversibility to
albuterol sulfate, study (PINNACLE-1/PINNACLE-2/
PINNACLE-4), treatment, visit, and treatment by visit
interaction as covariates. The time to first COPD exacer-
bation, time to treatment failure, and time to first CID
were analyzed using Cox regression models that adjusted
for baseline percent predicted FEV1, study, baseline CAT
score, baseline COPD exacerbation history (yes/no),
smoking status at baseline (former/current), baseline
continuous eosinophil count, and ICS use at baseline
(yes/no). The rate of moderate or severe COPD exacer-
bations was analyzed using negative binomial regression,adjusting for the same covariates, with treatment expos-
ure used as an offset variable. Patients who did not ex-
perience a COPD exacerbation were censored at week
24, and those who withdrew from the study without ex-
periencing a COPD exacerbation were censored at the
date of withdrawal.
Results
Patient population
A total of 5000 patients were included in the pooled
safety population (Fig. 2). Of these, 4983 were included
in the pooled ITT population.
Baseline demographics and clinical characteristics were
generally similar across the ITT populations of all three
studies, with some differences observed in race, gender,
body mass index, smoking status, and symptom burden
(as measured by CAT score), mainly due to the inclusion
of Asian patients in PINNACLE-4 [7, 9]. Most of the
Asian patients recruited in PINNACLE-4 were male, and
had, on average, a lower baseline CAT score than pa-
tients from other regions. Accordingly, the proportion of
male patients in PINNACLE-4 (74.1%) was higher than
in PINNACLE-1 and -2 (56.4 and 55.1%, respectively),
and fewer patients in PINNACLE-4 had CAT scores ≥15
compared with PINNACLE-1 or -2 (48.3% vs. 68.2 and
69.5%, respectively). A greater proportion of patients in
PINNACLE-1 and -2 were current smokers (54.1 and
53.2%, respectively) than in PINNACLE-4 (44.9%).
Baseline characteristics for the pooled ITT population,
symptomatic, and exacerbation history subgroups are
shown in Table 1. As expected, a larger proportion of
patients in the exacerbation history subgroup reported
ICS use at screening (47.3%) compared with the pooled
ITT population and symptomatic subgroup (34.6–
35.8%). Within the pooled ITT population and the
symptomatic and exacerbation history subgroups, base-
line demographics were generally similar across treat-
ment groups (data not shown).
Efficacy
Lung function
In the pooled ITT population, treatment with GFF MDI
improved morning pre-dose trough FEV1 at week 24
versus GP MDI (least squares mean [LSM] difference
[95% confidence interval (CI)]: 59mL [43, 75mL]), FF MDI
(LSM difference [95% CI]: 65mL [48, 81mL]) and placebo
MDI (LSM difference [95% CI]: 146mL [125, 166mL]), all
p < 0.0001; Figs. 3a and 4a. These findings were consistent
with the results for GFF MDI versus comparators in
all three PINNACLE studies (Fig. 3a; all comparisons
p ≤ 0.0003). The improvements with GFF MDI versus
comparators in morning pre-dose trough FEV1 over
time in the pooled ITT population further supported
the results of the individual studies (Fig. 4a). In both
Fig. 2 Patient disposition (pooled PINNACLE population). Patients were excluded from the pooled population if they did not receive any study
treatment or if they had overlapping treatment exposure from enrollment in more than one PINNACLE study (further details are provided in the
Methods). FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; MDI, metered dose inhaler.
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treatment differences for GFF MDI versus placebo MDI
consistently exceeded the minimal clinically important dif-
ference (MCID) threshold of 100mL [12].
The treatment benefits with GFF MDI versus compar-
ators observed over 24 weeks in the individual studies
and pooled analysis were comparable to those observed
at week 24 (all p < 0.0001; Additional file 1: Fig. S1(a)).
GP MDI and FF MDI monotherapies consistently im-
proved morning pre-dose trough FEV1 at week 24 and
over 24 weeks compared to placebo MDI (all p ≤ 0.0138).
The peak change from baseline in FEV1 within 2 h
post-dose at week 24 and over 24 weeks was significantly
improved by GFF MDI versus monocomponents and
placebo MDI in the pooled analysis as well as all three
PINNACLE studies (all p < 0.0001; Figs. 3b, 4b, and Add-
itional file 1: Fig. S1(b)). GP MDI and FF MDI also im-
proved peak FEV1 at week 24 and over 24 weeks versus
placebo MDI (all p < 0.0001).
Exacerbations
In the pooled ITT population, the proportion of patients
who experienced a moderate or severe COPD exacerba-
tion in the GFF MDI treatment arm was 17.7%, compared
with 20.2, 19.1, and 21.6% in the GP MDI, FF MDI, and
placebo MDI groups, respectively (Additional file 1: Table
S1). GFF MDI delayed the time to first moderate or severe
COPD exacerbation compared with GP MDI, FF MDI,
and placebo MDI, with the difference versus comparatorsmaintained over the treatment period in the pooled ITT
population, the exacerbation history subgroup and the
symptomatic subgroup (Fig. 5).
GFF MDI reduced the risk of a moderate or severe
COPD exacerbation compared with GP MDI (hazard ratio
[HR] [95% CI] 0.82 [0.69, 0.96]; p = 0.0168), FF MDI (HR
[95% CI] 0.85 [0.72, 1.01]; p = 0.0628) and placebo MDI
(HR [95% CI] 0.72 [0.59, 0.88]; p = 0.0012; Fig. 6a). Com-
pared with the pooled ITT population, the proportions of
patients who experienced a moderate or severe COPD ex-
acerbation were slightly larger in the symptomatic sub-
group (GFF MDI [18.7%], GP MDI [23.3%], FF MDI
[21.5%], and placebo MDI [24.8%]), and as expected
were noticeably larger in the exacerbation history subgroup
(GFF MDI [28.9%], GP MDI [33.4%], FF MDI [32.8%], and
placebo MDI [33.0%]; Additional file 1: Table S1). In gen-
eral, the magnitude of treatment benefit in reducing the risk
of a moderate or severe COPD exacerbation was greater
with GFF MDI versus comparators in the exacerbation his-
tory and symptomatic subgroups than the pooled ITT
population, as indicated by smaller hazard ratios (Fig. 6a).
The annualized rate of moderate or severe exacerba-
tions was also numerically lower with GFF MDI versus
monocomponents and placebo MDI in all the analysis
populations (Additional file 1: Table S1).
Treatment failure
Treatment failure with GFF MDI was observed in 27.6%
of patients (n = 438), compared with 31.6% of patients
Table 1 Patient demographics and clinical characteristics (pooled ITT, exacerbation history, and CAT ≥15 populations)
Pooled ITT
(n = 4983)
Exac. historya
(n = 1246)
CAT ≥15
(n = 3082)
Mean age, years (SD) 63.3 (8.1) 62.8 (8.1) 62.1 (8.2)
Age≥65 years, n (%) 2339 (46.9) 551 (44.2) 1243 (40.3)
Male, n (%) 3086 (61.9) 705 (56.6) 1774 (57.6)
Race, n (%)
White 3944 (79.1) 958 (76.9) 2653 (86.1)
Asian 711 (14.3) 203 (16.3) 192 (6.2)
Black 302 (6.1) 80 (6.4) 218 (7.1)
Other 26 (0.5) 5 (0.4) 19 (0.6)
Current smoker, n (%) 2528 (50.7) 588 (47.2) 1824 (59.2)
Mean number of pack-years smokedb (SD) 49.3 (26.1) 48.6 (25.8) 50.7 (26.3)
Mean number of years smoked (SD) 39.4 (10.3) 38.8 (10.3) 40.2 (9.9)
Mean total CAT scorec (SD) 17.3 (7.5) 18.1 (7.6) 22.0 (5.2)
CAT ≥10, n (%) 4166 (83.6) 1064 (85.4) 3082 (100.0)
CAT ≥15, n (%) 3082 (61.9) 823 (66.1) 3082 (100.0)
CAT ≥20, n (%) 1879 (37.7) 519 (41.7) 1879 (61.0)
ICS use at baseline, n (%) 1723 (34.6) 589 (47.3) 1104 (35.8)
Exacerbation history in the past year, n (%)
≥1 moderate or severe exacerbation 1246 (25.0) 1246 (100.0) 823 (26.7)
≥1 severe exacerbation 302 (6.1) 302 (24.2) 211 (6.8)
COPD severity, n (%)
Mildd 30 (0.6) 6 (0.5) 8 (0.3)
Moderate 2764 (55.5) 619 (49.7) 1558 (50.6)
Severe 1971 (39.6) 551 (44.2) 1344 (43.6)
Very severe 218 (4.4) 70 (5.6) 172 (5.6)
GOLD 2017 Category, n (%)
A 729 (14.6) 105 (8.4) 0
B 3693 (74.1) 591 (47.4) 2705 (87.8)
C 73 (1.5) 73 (5.9) 0
D 473 (9.5) 473 (38.0) 377 (12.2)
Missing 15 (0.3) 4 (0.3) 0
Mean COPD duration, yearse (SD) 7.2 (6.3) 7.4 (6.1) 7.6 (6.4)
Mean pre-bronchodilator FEV1, % predicted (SD) 45.1 (13.8) 43.2 (13.6) 43.5 (13.7)
Mean post-bronchodilator FEV1, % predicted (SD) 52.5 (13.9)
f 50.8 (14.0) 50.9 (13.9)
Mean pre-bronchodilator FVC, % predicted (SD) 71.2 (16.2) 70.0 (15.9) 68.6 (15.7)
Mean post-bronchodilator FVC, % predicted (SD) 80.0 (16.3)f 79.5 (16.3) 77.5 (15.8)
aThe exacerbation history population includes patients with ≥1 moderate or severe exacerbation in the previous year
bPack-years smoked = (number of cigarettes per day/20)* number of years smoked
cn = 4968 (pooled ITT), n = 1242 (Exac. history)
dCharacterized as mild COPD due to the application of an Asian correction factor in PINNACLE-4, and were identified as protocol deviations
en = 4970 (pooled ITT), n = 1243 (Exac. history), n = 3076 (CAT ≥15)
fn = 4981
CAT COPD assessment test, COPD chronic obstructive pulmonary disease, Exac. exacerbation, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity,
GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, ITT intent-to-treat, SD standard deviation
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and 36.8% with placebo MDI (n = 249; Additional file 1:
Table S2). In the pooled ITT population, GFF MDIreduced the risk of treatment failure by 18% (p = 0.0043),
16% (p = 0.0107), and 34% (p < 0.0001) versus GP MDI,
FF MDI, and placebo MDI, respectively (Fig. 6b). In line
Fig. 3 Lung function endpoints at week 24. Change from baseline in morning pre-dose trough FEV1 (a) and peak change from baseline in FEV1
within 2 h post-dose (b) (ITT population of the individual and pooled studies). Data are least squares mean treatment differences (95% confidence
intervals) shown in mL. p < 0.0001 for all comparisons except for trough FEV1 in PINNACLE-2, GFF MDI versus GP MDI (p = 0.0003) and FF MDI
(p = 0.0002). Data for PINNACLE-1, -2, and -4 studies have been published previously [7, 9]. FEV1, forced expiratory volume in 1 s; FF, formoterol
fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; MDI, metered dose inhaler
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tory and symptomatic subgroups generally experienced
similar or larger reductions in the risk of treatment fail-
ure with GFF MDI versus comparators than the pooled
ITT population (Fig. 6b, Additional file 1: Table S2).CID
A CID event occurred in 58.4% of patients (n = 925)
treated with GFF MDI, compared with 66.0% (n = 899),
62.1% (n = 845), and 74.4% (n = 503) of patients who re-
ceived GP MDI, FF MDI, and placebo MDI, respectively
(Additional file 1: Table S2). GFF MDI reduced the risk
of CID versus GP MDI, FF MDI, and placebo MDI in
the pooled ITT population (23, 17, and 49% reductions,
respectively; all p < 0.0001), with similar effects observedin the exacerbation history and symptomatic subgroups
(all p < 0.05) (Fig. 6c, Additional file 1: Table S2).Safety
Overall, the incidences of treatment-emergent adverse
events (TEAEs), drug-related TEAEs, TEAEs leading to
early discontinuation, and serious TEAEs were similar
across treatment groups (Table 2). Most TEAEs were
mild to moderate in severity, with severity comparable
across treatment groups. The most commonly reported
TEAEs overall were upper respiratory tract infection,
viral upper respiratory tract infection, and cough (4.8,
4.7, and 2.7%, respectively in the pooled population, and
4.4, 4.7 and 3.4%, respectively in the GFF MDI group)
(Table 2).
Fig. 4 Lung function endpoints over time. Change from baseline in morning pre-dose trough FEV1 (a) and peak change from baseline in FEV1
within 2 h post-dose (b) (pooled ITT population). Data are least squares mean ± standard error. FEV1, forced expiratory volume in 1 s;
FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; MDI, metered
dose inhaler
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across the three pivotal Phase III 24-week studies. None
of the deaths were considered by the investigator to be
related to the study drug, and two occurred within
14 days post-treatment. A total of 6 patients in the
GFF MDI group (0.4%) and 2 patients in each of the
GP MDI, FF MDI, and placebo MDI groups (0.1–0.3%)
experienced a fatal event. Six deaths had a probable
cardiovascular cause (GFF MDI, n = 3; GP MDI, n = 1;
FF MDI, n = 2); none had a probable respiratory cause
(full details are provided in Additional file 1: File A1).
Overall, the pooled safety analysis identified no new
safety concerns among the most commonly-reported
TEAEs, and no clinically meaningful differences were
observed between treatment groups.
Discussion
This pooled analysis of data from PINNACLE-1, -2, and
-4 illustrates consistent lung function benefits across the
individual studies, with improvements in the changefrom baseline in morning pre-dose trough FEV1 at week
24 and over 24 weeks with GFF MDI versus placebo
MDI exceeding the MCID of 100 mL [12]. GFF MDI
also consistently provided significant improvements in
trough FEV1 and peak change from baseline in FEV1
within 2 h post-dose compared with GP MDI and FF MDI
[7, 9]. Improvements in lung function in the PINNACLE
studies were generally similar to those reported in other
pivotal studies of LAMA/LABA FDCs [10, 11, 13]. A net-
work meta-analysis performed using all available data of
fixed-dose LAMA/LABA combinations (including the
PINNACLE studies) also found that GFF MDI had com-
parable efficacy to other LAMA/LABAs in improving lung
function [14].
Pooling data across the three pivotal PINNACLE stud-
ies allowed for assessment of study endpoints, which
were not well powered in the individual studies, such as
differential treatment effects on COPD exacerbations.
Many studies assessing COPD symptom and exacerba-
tion endpoints enroll patients with a high symptom
Fig. 5 Time to first moderate or severe COPD exacerbation in the pooled ITT population (a), exacerbation history population (b), and CAT ≥15
population (c). The exacerbation history population includes patients with ≥1 moderate or severe exacerbations in the previous year.
CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol
fumarate; GP, glycopyrrolate; ITT, intent-to-treat; MDI, metered dose inhaler.
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more substantial treatment effects. Notably, even though
the PINNACLE studies did not enrich the patient popu-
lation for these characteristics, clinically meaningful re-
ductions in the risk of a moderate or severe COPD
exacerbation, treatment failure, and CID were observed
with GFF MDI compared with GP MDI, FF MDI, and
placebo MDI in the pooled ITT population.Given that the inclusion criteria of the PINNACLE
studies did not enrich the study population for patients
with a high symptom burden or exacerbation history,
the integrated analyses included subgroups that exam-
ined the impact of two risk factors for exacerbations
(high symptom burden [CAT score ≥15] and/or a recent
exacerbation history [≥1 moderate or severe exacerba-
tions in the past year]) on treatment benefit. While the
Fig. 6 Time to first moderate or severe COPD exacerbation (a), time to treatment failure (b), and time to first CID (c) in the pooled ITT,
exacerbation history, and CAT ≥15 populations. Data are hazard ratios (95% confidence intervals). *p < 0.05; **p < 0.01; ***p < 0.001; †p < 0.0001. The
exacerbation history population includes patients with ≥1 moderate or severe exacerbations in the previous year. CAT, COPD assessment test;
CID, clinically important deterioration; COPD, chronic obstructive pulmonary disease; Exac., exacerbation; FF, formoterol fumarate; GFF,
glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; MDI, metered dose inhaler.
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tomatic patients [1], this pooled analysis defined the
symptomatic population as CAT ≥15 based on the
threshold pre-specified in the PINNACLE-4 analysis
plan. Previous pooled findings from PINNACLE-1 and
-2 have shown that results for CAT ≥10 and CAT ≥15
subgroups were generally similar [6]. Exacerbation re-
ductions for GFF MDI versus monocomponents were
greater in symptomatic patients and those with a previ-
ous exacerbation history compared to the pooled ITTpopulation (as indicated by smaller hazard ratios), sug-
gesting that these subgroups of patients may derive an
even larger benefit from LAMA/LABA treatment com-
pared with monotherapies. The pooled ITT and symp-
tomatic populations experienced similar treatment
benefits with regard to the time to first CID. However,
this was not unexpected considering that the time to
first CID was primarily driven by the ≥100 mL decline in
morning pre-dose trough FEV1, and a previous analysis
of pooled data from PINNACLE-1 and -2 showed that
Table 2 Summary of safety data (pooled safety population)
GFF MDI 18/9.6 μg
(n = 1588)
GP MDI 18 μg
(n = 1364)
FF MDI 9.6 μg
(n = 1370)
Placebo MDI
(n = 678)
All patients
(n = 5000)
TEAEs, n (%) [number of events]
≥ 1 TEAE 923 (58.1) [2317] 750 (55.0) [1946] 762 (55.6) [1866] 386 (56.9) [921] 2821 (56.4) [7050]
Mild 396 (24.9) 317 (23.2) 348 (25.4) 174 (25.7) 1235 (24.7)
Moderate 404 (25.4) 326 (23.9) 308 (22.5) 162 (23.9) 1200 (24.0)
Severe 123 (7.7) 107 (7.8) 106 (7.7) 50 (7.4) 386 (7.7)
Drug-relateda TEAEs 172 (10.8) [276] 150 (11.0) [256] 144 (10.5) [228] 69 (10.2) [115] 535 (10.7) [875]
Serious TEAEs 133 (8.4) [171] 107 (7.8) [155] 106 (7.7) [129] 50 (7.4) [65] 396 (7.9) [520]
Drug-relateda serious TEAEs 10 (0.6) [11] 15 (1.1) [21] 8 (0.6) [9] 3 (0.4) [3] 36 (0.7) [44]
TEAEs leading to early discontinuation 91 (5.7) [125] 80 (5.9) [133] 71 (5.2) [120] 43 (6.3) [56] 285 (5.7) [434]
Deaths (all causes)
Treatment period 5 (0.3) 1 (0.1) 2 (0.1) 2 (0.3) 10 (0.2)
Treatment period + 14 days 6 (0.4) 2 (0.1) 2 (0.1) 2 (0.3) 12 (0.2)
TEAEs occurring in ≥2% of patients in any treatment arm, preferred term, n (%)
Upper respiratory tract infection 70 (4.4) 67 (4.9) 59 (4.3) 42 (6.2) 238 (4.8)
Viral upper respiratory tract infection 75 (4.7) 61 (4.5) 71 (5.2) 26 (3.8) 233 (4.7)
Cough 54 (3.4) 37 (2.7) 32 (2.3) 14 (2.1) 137 (2.7)
COPDb 40 (2.5) 42 (3.1) 30 (2.2) 20 (2.9) 132 (2.6)
Dyspnea 35 (2.2) 32 (2.3) 35 (2.6) 26 (3.8) 128 (2.6)
Nasopharyngitis 45 (2.8) 25 (1.8) 29 (2.1) 19 (2.8) 118 (2.4)
Sinusitis 28 (1.8) 27 (2.0) 33 (2.4) 16 (2.4) 104 (2.1)
Headache 30 (1.9) 31 (2.3) 35 (2.6) 7 (1.0) 103 (2.1)
Back pain 36 (2.3) 29 (2.1) 25 (1.8) 11 (1.6) 101 (2.0)
Bronchitis 24 (1.5) 35 (2.6) 18 (1.3) 17 (2.5) 94 (1.9)
Hypertension 28 (1.8) 20 (1.5) 21 (1.5) 24 (3.5) 93 (1.9)
Pneumonia 28 (1.8) 24 (1.8) 18 (1.3) 17 (2.5) 87 (1.7)
Urinary tract infection 33 (2.1) 21 (1.5) 14 (1.0) 12 (1.8) 80 (1.6)
aPossibly, probably, or definitely related to study drug, as per investigator’s judgment prior to unblinding. bWorsening of COPD defined as a COPD exacerbation
since the patient’s last visit. COPD exacerbations were only recorded as an AE if they were considered to be a serious TEAE
COPD chronic obstructive pulmonary disease, FF formoterol fumarate, GFF glycopyrrolate/formoterol fumarate, GP glycopyrrolate, MDI metered dose inhaler,
TEAE treatment-emergent adverse event
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trough FEV1 was independent of patient baseline CAT
scores [6], and would also not be expected to relate to
exacerbation history.
The exacerbations treatment pathway described in the
GOLD 2020 Report recommends dual LAMA/LABA
combination therapy for patients in whom an individual
LAMA or LABA is not adequately controlling COPD ex-
acerbations unless they have a blood eosinophil count
≥300 cells/μL or a high risk of further exacerbations [1].
The decreased risk of exacerbations demonstrated with
GFF MDI relative to GP MDI and FF MDI in patients
with moderate-to-very severe COPD from the PINNA-
CLE studies supports this treatment recommendation.
However, the comparable safety profile between
GFF MDI, GP MDI and FF MDI, and the fact that
treatment differences in exacerbation risk were observedeven in a population including low-risk patients, supports
the use of dual LAMA/LABA therapy regardless of pa-
tients’ symptom burden and exacerbation history in order
to reduce the chance of experiencing an exacerbation that
could substantially impact their lung function and quality
of life [2, 3].
The PINNACLE studies also assessed dyspnea using
the transition dyspnea index (TDI) scale [9, 16]. How-
ever, it was not feasible to pool these data, as
PINNACLE-1 and -2 used a self-administered computer-
ized (SAC) version of the tool, while PINNACLE-4 used
the more established paper interviewer-administered
version, and thus this endpoint was not included in the
pooled analysis. The SAC TDI is reported on a continu-
ous scale, while the interviewer-administered TDI is on
an integer Likert scale [17–19]. All three PINNACLE
studies assessed quality of life using the SGRQ [7, 9],
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due to variation in the findings between PINNACLE-1
and -2 versus PINNACLE-4. The changes from baseline
in SGRQ total score at week 24 with all active treat-
ments were greater in PINNACLE-4 than in
PINNACLE-1 and -2 [7, 9], which may relate to the geo-
graphic difference in the populations studied and the
modifying effect of socioeconomic status on quality of
life outcomes [20].
The analysis of pooled safety data enabled the safety
and tolerability of GFF MDI to be investigated in a much
larger patient population than any of the individual stud-
ies alone. The results in the pooled population were
commensurate with the individual studies [7, 9], and
demonstrated that all treatments were well tolerated,
with no unexpected safety signals identified.
Limitations of the analyses include the fact that the
three individual studies were produced at different times
and, accordingly, some of the pooled analyses were spe-
cified after results from PINNACLE-1 and -2 were avail-
able (but before the unblinding of PINNACLE-4 data). It
should be noted that GFF MDI and the comparators
used in the PINNACLE studies were all formulated
using co-suspension delivery technology (other than tio-
tropium in PINNACLE-1). Hence, these studies could
not assess the potential impact of the co-suspension
delivery technology on clinical outcomes.
While many studies that evaluate COPD exacerbations
are conducted over 52 weeks [15, 21, 22], the PINNA-
CLE studies were 24 weeks in duration. However, due to
the large number of patients (n = 4983) and patient-
years of exposure (> 2000), the fact that patients were re-
cruited across all four seasons of the year in each study,
and the use of time-to-event analyses to handle censor-
ing due to study discontinuation following a COPD ex-
acerbation, this pooled analysis provides a compelling
body of evidence for the benefit of GFF MDI in prevent-
ing exacerbations.
Conclusions
Pooled analyses of lung function endpoints (pre-dose
trough FEV1 and peak FEV1) from the PINNACLE stud-
ies supported the findings from the individual studies,
with GFF MDI 18/9.6 μg demonstrating significant, clin-
ically meaningful improvements versus placebo and
monocomponents in patients with moderate-to-very se-
vere COPD. GFF MDI reduced the risk of moderate or
severe COPD exacerbations, CID, and treatment failure
compared with monocomponents and placebo MDI,
even in a patient population that was not enriched for
symptoms or exacerbation history. Treatment benefits
for GFF MDI versus monotherapies on exacerbation risk
were generally even greater in subgroups of patients with
higher symptom burden (CAT score ≥15) and those withan exacerbation history (≥1 moderate or severe exacer-
bation in the past year), providing additional support for
the importance of LAMA/LABA therapy in these patient
populations.
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